{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:01:26Z","timestamp":1784588486004,"version":"3.55.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP25K12587"],"award-info":[{"award-number":["JP25K12587"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the short-term efficacy and safety of enfortumab vedotin plus pembrolizumab (EV\u00a0+\u00a0P) as a first-line systemic therapy for patients with advanced urothelial carcinoma (UC) in real-world practice, with a focus on cisplatin (CDDP) eligibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventy-six patients who received EV\u00a0+\u00a0P treatment for advanced UC at 13 institutions between November 2024 and March 2025 were retrospectively included in this study. We collected the clinical characteristics and treatment data of the patients and assessed treatment response, progression-free survival (PFS), and adverse events (AEs). Patients were divided into two groups based on CDDP eligibility, and both efficacy and safety were compared between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median observation period was 5.56 (IQR, 4.77\u20136.21) months. Complete response was achieved in 6 (7.9%) patients receiving EV\u00a0+\u00a0P, partial response in 40 (52.6%), stable disease in 20 (26.3%), and progressive disease in 10 (13.2%). Six-month and median PFS rates were 80.6% and not reached, respectively. AEs of any grade and grade \u22653 occurred in 59 (77.6%) and 25 (32.9%) patients, respectively. The most frequently observed AE was skin disorders, which occurred in 36 (47.4%) patients; no grade 5 AEs were observed. Treatment response, PFS, and the cumulative incidence of AEs did not differ between CDDP-ineligible and CDDP-eligible patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The short-term efficacy of EV\u00a0+\u00a0P treatment seemed comparable to that in previous reports, and the safety profile was acceptable, regardless of CDDP eligibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag117","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:51:31Z","timestamp":1783597891000},"source":"Crossref","is-referenced-by-count":0,"title":["Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-3087","authenticated-orcid":false,"given":"Takuji","family":"Hayashi","sequence":"first","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-4264","authenticated-orcid":false,"given":"Atsunari","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishizuya","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7413-0755","authenticated-orcid":false,"given":"Hiromu","family":"Horitani","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Inoguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Horibe","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Sassi","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka International Cancer Institute , Osaka, Osaka, 3-1-69 Otemae, Chuo-ku, Osaka 540-0008 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ujike","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Rosai Hospital , Sakai, Osaka, 1179-3 Nagasonecho, Kita-ku, Sakai 591-8025 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka General Medical Center , Osaka, Osaka, 3-1-56 Bandaihigaishi, Sumiyoshi-ku, Osaka 558-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Urology, Toyonaka Municipal Hospital , Toyonaka, Osaka, 4-14-1 Shibaharacho, Toyonaka 560-8565 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Urology, Sakai City Medical Center , Sakai, Osaka, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai 593-8304 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yazawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Keisatsu Hospital , Osaka, Osaka, 2-6-40 Karasugatsuji, Tennoji-ku, Osaka 543-0042 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Urology, Minoh City Hospital , Minoh, Osaka, 5-7-1 Kayano, Minoh 562-0014 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kurahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Hyogo Prefectural Nishinomiya Hospital , Nishinomiya, Hyogo, 13-9 Rokutanji-cho, Nishinomiya, 662-0918 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Urology, Ikeda City Hospital , Ikeda, Osaka, 3-1-14 Jonan, Ikeda 563-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Asakura","sequence":"additional","affiliation":[{"name":"Department of Urology, Nippon Life Hospital , Osaka, Osaka, 2-1-54 Enokojima, Nishi-ku, Osaka 550-0006 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Murakawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Higashiosaka City Medical Center , Higashiosaka, Osaka, 3-4-5 Nishiiwata, Higashiosaka 578-8588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Urology, National Hospital Organization Osaka National Hospital , Osaka, Osaka, 2-1-14 Hoenzaka, Chuo-ku, Osaka 540-0006 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka International Cancer Institute , Osaka, Osaka, 3-1-69 Otemae, Chuo-ku, Osaka 540-0008 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taigo","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Osaka Graduate School of Medicine , 2-2, Yamadaoka, Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072018033090000_ref1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026072018033090000_ref2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur Urol"},{"key":"2026072018033090000_ref3","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026072018033090000_ref4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026072018033090000_ref5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"2026072018033090000_ref6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2026072018033090000_ref7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072018033090000_ref8","doi-asserted-by":"publisher","first-page":"102453","DOI":"10.1016\/j.clgc.2025.102453","article-title":"Real-world outcomes of enfortumab vedotin and pembrolizumab in advanced urothelial carcinoma: a multicenter retrospective analysis","volume":"23","author":"Jain","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"2026072018033090000_ref9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/jjco\/hyaf182","article-title":"Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study","volume":"56","author":"Iwatani","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"2026072018033090000_ref10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2026072018033090000_ref11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/iju.15368","article-title":"Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study","volume":"31","author":"Fukuokaya","year":"2024","journal-title":"Int J Urol"},{"key":"2026072018033090000_ref12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study","volume":"29","author":"Taoka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2026072018033090000_ref13","doi-asserted-by":"publisher","first-page":"105544","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","volume":"10","author":"Heijden","year":"2025","journal-title":"ESMO Open"},{"key":"2026072018033090000_ref14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"2026072018033090000_ref15","doi-asserted-by":"publisher","first-page":"177.e1","DOI":"10.1016\/j.urolonc.2024.03.001","article-title":"Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer","volume":"42","author":"Mamtani","year":"2024","journal-title":"Urol Oncol"},{"key":"2026072018033090000_ref16","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1007\/s11255-025-04462-w","article-title":"Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma","volume":"57","author":"Hara","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"2026072018033090000_ref17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.21873\/invivo.13961","article-title":"Steroid premedication impact on efficacy and cutaneous toxicity of enfortumab vedotin for advanced urothelial carcinoma","volume":"39","author":"Furubayashi","year":"2025","journal-title":"In Vivo"},{"key":"2026072018033090000_ref18","doi-asserted-by":"publisher","first-page":"e70425","DOI":"10.1111\/iju.70425","article-title":"Association of Prophylactic Intravenous Corticosteroid Premedication with toxicity and survival in patients receiving enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"33","author":"Shinohara","year":"2026","journal-title":"Int J Urol"},{"key":"2026072018033090000_ref19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/cancers18050739","article-title":"Real-world safety and early effectiveness of first-line enfortumab vedotin plus Pembrolizumab with routine dexamethasone premedication in advanced urothelial carcinoma","volume":"18","author":"Hara","year":"2026","journal-title":"Cancers (Basel)"},{"key":"2026072018033090000_ref20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"2026072018033090000_ref21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13543784.2025.2473695","article-title":"Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma","volume":"34","author":"Santoni","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"2026072018033090000_ref22","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10147-025-02822-1","article-title":"Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study","volume":"30","author":"Ikarashi","year":"2025","journal-title":"Int J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag117\/69579579\/hyag117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag117\/69579579\/hyag117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:03:38Z","timestamp":1784585018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag117\/8738432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag117","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"hyag117"}}